XM Amerika Qoʻshma Shtatlari fuqarolariga xizmat koʻrsatmaydi.

XM Amerika Qoʻshma Shtatlari fuqarolariga xizmat koʻrsatmaydi.
S
S

Sage

Yangiliklar

Reuters - 6 kun oldin

Sage Therapeutics CFO Kimi Iguchi resigns from position

BRIEF-Sage Therapeutics CFO Kimi Iguchi resigns from position Nov 1 (Reuters) - SAGE Therapeutics Inc SAGE.O : SAGE THERAPEUTICS: RESIGNATION OF KIMI IGUCHI FROM HER POSITION AS CFO OF CO Source text: [ID:n0001193125-24-249830] Further company coverage: SAGE.O
S
Reuters - 1 hafta oldin

SAGE Therapeutics Inc reports results for the quarter ended in January 1 - Earnings Summary

SAGE Therapeutics Inc reports results for the quarter ended in January 1 - Earnings Summary SAGE Therapeutics Inc SAGE.OQ reported a quarterly adjusted loss of $1.53​​ per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of $-3.37. The mean expectation of nineteen analysts for the quarter was for a loss of $1.53 per share.
S
Reuters - 2 hafta oldin

SAGE Therapeutics Inc <SAGE.OQ> expected to post a loss of $1.53 a share - Earnings Preview

SAGE Therapeutics Inc expected to post a loss of $1.53 a share - Earnings Preview SAGE Therapeutics Inc SAGE.OQ SAGE.O is expected to show a rise in quarterly revenue when it reports results on October 29 for the period ending September 30 2024 The Cambridge Massachusetts-based company is expected to report a 297.7% increase in revenue to $10.802 million from $2.72 million a year ago, according to the mean estimate from 19 analysts, based on LSEG data.
S
Reuters - 3 hafta oldin

U.S. STOCKS Avery Dennison, Snap-On, Avadel Pharma

BUZZ-U.S. STOCKS ON THE MOVE-Avery Dennison, Snap-On, Avadel Pharma Wall Street rose on Thursday, with the S&P 500 and the Dow briefly reaching record highs, as chip stocks surged on TSMC's upbeat forecast and stronger-than-expected monthly retail sales indicated a robust U.S. consumer. .N At 13:36 ET, the Dow Jones Industrial Average .DJI was up 0
A
B
C
E
I
N
N
S
S
S
U
U
U
U
A
E
Reuters - 3 hafta oldin

U.S. STOCKS Avery Dennison, Snap-On, Avadel Pharma

BUZZ-U.S. STOCKS ON THE MOVE-Avery Dennison, Snap-On, Avadel Pharma Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street gained on Thursday, with the S&P 500 and the Dow touching intraday record highs, driven by TSMC's upbeat forecast and a bigger-than-expected rise in monthly retail sales indicating a strong U.S.
A
B
C
E
I
N
N
R
S
S
S
U
U
U
U
T
U
W
W
A
E
M
S
Reuters - 3 hafta oldin

Sage to lay off more than half of R&D team, shares fall

BUZZ-Sage to lay off more than half of R&D team, shares fall ** Sage Therapeutics' shares SAGE.O fall 5.5% to $6.87 in morning trade ** Co says it will lay off more than 165 employees, including more than half of its R&D team, as part of reorganization plan ** To prioritize launch of postpartum depression pill Zurzuvae, which has been jointly devel
B
S
Reuters - 3 hafta oldin

SAGE Therapeutics Approved Separation Of CFO Kimi Iguchi And Anne Cook, Senior VP, General Counsel, And Secretary

BRIEF-SAGE Therapeutics Approved Separation Of CFO Kimi Iguchi And Anne Cook, Senior VP, General Counsel, And Secretary Oct 17 (Reuters) - SAGE Therapeutics Inc SAGE.O : SAGE THERAPEUTICS: APPROVED SEPARATION OF KIMI IGUCHI, CFO, AND ANNE MARIE COOK, SENIOR VP, GENERAL COUNSEL, AND SECRETARY Source text for Eikon: [ID:n0001193125-24-238425] Further
S
Reuters - 3 hafta oldin

SAGE Therapeutics Says To Reduce Workforce By About 33%

BRIEF-SAGE Therapeutics Says To Reduce Workforce By About 33% Oct 17 (Reuters) - SAGE Therapeutics Inc SAGE.O : SAGE THERAPEUTICS ANNOUNCES STRATEGIC REORGANIZATION TO PRIORITIZE ZURZUVAE® COMMERCIALIZATION AND FOCUS ITS DEVELOPMENT PORTFOLIO SAGE THERAPEUTICS INC - TO REDUCE WORKFORCE BY APPROXIMATELY 33% SAGE THERAPEUTICS INC - REORGANIZATION TO
S
Reuters - 3 hafta oldin

Sage Therapeutics' CFO to leave, drugmaker to lay off over 165 employees

UPDATE 2-Sage Therapeutics' CFO to leave, drugmaker to lay off over 165 employees Adds details on CFO leaving company in paragraphs 1, 3 and background in paragraphs 8-10 Oct 17 (Reuters) - Sage Therapeutics SAGE.O said on Thursday its finance chief will leave the company and the drugmaker plans to lay off more than 165 employees as part of a reorganization plan that aims to focus on the launch of its postpartum depression pill.
B
S
Reuters - 3 hafta oldin

Sage Therapeutics to lay off more than 165 employees

Sage Therapeutics to lay off more than 165 employees Oct 17 (Reuters) - Sage Therapeutics SAGE.O said on Thursday it will lay off more than 165 employees or about 33% of the company's total workforce. Reporting by Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta
S
Reuters - 3 hafta oldin

U.S. Autozone, State Street, UnitedHealth

U.S. RESEARCH ROUNDUP-Autozone, State Street, UnitedHealth Oct 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Autozone, State Street and UnitedHealth, on Wednesday. HIGHLIGHTS * Autozone Inc AZO.N : Roth MKM resumes coverage with buy rating; price target $3,634 * Goldman Sachs GS.N : Barclays raises target price to $588 from $565 * ServiceNow Inc NOW.N : Jefferies raises target price to $1,100 from $900 * State St
C
G
S
T
F
G
S
A
Reuters - 4 hafta oldin

U.S. Aflac, Lincoln National, Prudential Financial

U.S. RESEARCH ROUNDUP-Aflac, Lincoln National, Prudential Financial Oct 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aflac, Lincoln National and Prudential Financial, on Wednesday. HIGHLIGHTS * Aflac Inc AFL.N : TD Cowen initiates coverage with hold rating; price target $102 * Corebridge Financial Inc CRBG.N : TD Cowen initiates coverage with buy rating * Lincoln National Corp LNC.N : TD Cowen initiates coverage
A
B
G
H
N
P
S
S
S
A
V
A
A
E
G
L
M
Reuters - 4 hafta oldin

U.S. STOCKS Nvidia, Roblox, Honeywell

BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Roblox, Honeywell Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes opened higher on Tuesday, as investors shifted their attention to the upcoming third-quarter earnings season and inflation data for hints on the Federal Reserve's future rate decisions.
C
M
M
N
Q
S
L
R
W
U
U
E
S
T
Reuters - 4 hafta oldin

U.S. STOCKS Copper miners, PepsiCo, Casinos

BUZZ-U.S. STOCKS ON THE MOVE-Copper miners, PepsiCo, Casinos Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures bounced back on Tuesday from a selloff in the previous session, as investors turned their focus on key inflation data and third-quarter earnings later this week for fresh insights into the Federal Reserve's interest rate path.
M
M
P
Q
S
L
R
W
U
E
T
Reuters - 4 hafta oldin

Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide

UPDATE 3-Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide Adds background in paragraph 2, analyst comment in paragraph 5; updates shares Oct 8 (Reuters) - Sage Therapeutics SAGE.O said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after it failed to meet the main goal of a late-stage trial, sending its shares down 10% in premarket trading.
B
S
Reuters - 4 hafta oldin

Sage falls on plans to stop development of Alzheimer's disease drug

BUZZ-Sage falls on plans to stop development of Alzheimer's disease drug ** Shares of Sage Therapeutics SAGE.O down 13% at $5.86 before the bell ** SAGE plans to stop further development of its experimental drug, dalzanemdor, for Alzheimer's disease after it failed to meet the main goal of a mid-stage study ** Dalzanemdor was being tested to treat
S
Reuters - 4 hafta oldin

Sage Announces Results From Phase 2 Study Of Dalzanemdor In Treatment Of Mild Cognitive Impairment And Mild Dementia In Alzheimer’s Disease

BRIEF-Sage Announces Results From Phase 2 Study Of Dalzanemdor In Treatment Of Mild Cognitive Impairment And Mild Dementia In Alzheimer’s Disease Oct 8 (Reuters) - SAGE Therapeutics Inc SAGE.O : SAGE THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM THE PHASE 2 LIGHTWAVE STUDY OF DALZANEMDOR (SAGE-718) IN THE TREATMENT OF MILD COGNITIVE IMPAIRMENT AND
S
Reuters - 4 hafta oldin

Sage Therapeutics to discontinue development of Alzheimer’s drug

Sage Therapeutics to discontinue development of Alzheimer’s drug Oct 8 (Reuters) - Sage Therapeutics SAGE.O said on Tuesday it will discontinue the development of its Alzheimer's disease drug as it did not meet the main goal in a mid-stage trial. Reporting by Christy Santhosh; Editing by Pooja Desai
S
Reuters - 1 oy oldin

Sage Therapeutics falls after Biogen terminates tremor drug partnership

BUZZ-Sage Therapeutics falls after Biogen terminates tremor drug partnership ** Shares of drug developer Sage Therapeutics SAGE.O fall 1% to $6.95 premarket ** Company says partner Biogen BIIB.O has terminated a licensing deal for Sage's experimental drug to treat essential tremor, effective February 2025 ** Sage had discontinued development of the
B
S
Reuters - 1 oy oldin

SAGE Therapeutics Announces Discontinuation Of The Collaboration With Biogen On The Sage-324 Program

BRIEF-SAGE Therapeutics Announces Discontinuation Of The Collaboration With Biogen On The Sage-324 Program Sept 26 (Reuters) - SAGE Therapeutics Inc SAGE.O : SAGE THERAPEUTICS ANNOUNCES DISCONTINUATION OF THE COLLABORATION WITH BIOGEN ON THE SAGE-324 PROGRAM SAGE THERAPEUTICS INC - BIOGEN TERMINATES RIGHTS UNDER SAGE-324 PROGRAM SAGE THERAPEUTICS I
S

Shartlar

Ommabop aktivlar

Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.

Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi

Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.

Riskdan ogohlantirish: Kapitalingiz risk ostida. Kredit yordamiga ega mahsulotlar hammaga ham toʻgʻri kelmasligi mumkin. Bizning Risklardan ogohlantirishimiz bilan tanishib chiqing.